Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
Type:
Grant
Filed:
April 27, 2012
Date of Patent:
May 6, 2014
Assignee:
DYAX Corp.
Inventors:
Henry Blair, Thomas Beck, Robert C. Ladner
Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
Type:
Grant
Filed:
November 22, 2010
Date of Patent:
April 29, 2014
Assignee:
Dyax Corp.
Inventors:
Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
Type:
Application
Filed:
September 5, 2013
Publication date:
April 17, 2014
Applicant:
DYAX CORP.
Inventors:
AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN NUNN, RADHAKRISHNA PILLAI, SYBILLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATTHEW A. VON WRONSKI
Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
Type:
Grant
Filed:
April 26, 2010
Date of Patent:
March 11, 2014
Assignees:
Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.
Inventors:
Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
Type:
Grant
Filed:
September 23, 2010
Date of Patent:
March 4, 2014
Assignees:
Bracco Suisse SA, Dyax Corp.
Inventors:
Christophe Arbogast, Philippe Bussat, Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan, Aaron K. Sato, Sharon Michele Walker, Daniel T. Dransfield
Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
Type:
Grant
Filed:
June 8, 2009
Date of Patent:
February 4, 2014
Assignees:
Dyax Corp., Bracco Suisse SA
Inventors:
Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert C. Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Feng Yan, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski
Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
Type:
Grant
Filed:
December 20, 2010
Date of Patent:
January 21, 2014
Assignees:
Bracco Suisse SA, Dyax Corp.
Inventors:
Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Aaron K. Sato, Sharon Michele Walker, Daniel T. Dransfield
Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
Type:
Application
Filed:
July 9, 2013
Publication date:
December 12, 2013
Applicant:
Dyax Corp.
Inventors:
Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom
Abstract: Disclosed are methods of selecting phage encoding a target binding protein. The methods can include forming a mixture comprising a plurality of diverse display phage, a target, and a support, and forming phage immobilized to the support, each of which comprises a phage which binds the target and the target immobilized to the support. Phage that do not bind to the target are separated. Host cells are contacted with the phage immobilized to the support via binding to the target so that the host cells are infected by the phage immobilized to the support. Replicate phage are produced from the infected cells in the presence of the target immobilized to the support, thereby forming replicate phage immobilized to the support via binding to the support. Replicate phage that do not bind to the target are separated. Host cells are contacted with the replicate phage immobilized to the support.
Type:
Grant
Filed:
September 5, 2003
Date of Patent:
October 15, 2013
Assignee:
Dyax Corp.
Inventors:
Robert C. Ladner, Shannon Hogan, Kristin Rookey
Abstract: Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.
Type:
Application
Filed:
April 24, 2012
Publication date:
September 19, 2013
Applicant:
DYAX CORP.
Inventors:
Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
September 17, 2013
Assignee:
Dyax Corp.
Inventors:
Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
Type:
Grant
Filed:
December 28, 2011
Date of Patent:
August 6, 2013
Assignee:
Dyax Corp.
Inventors:
Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
Abstract: Methods and apparatus for tracking and monitoring information related to an attack caused by a disease. A portable electronic device such as a smartphone or portable computer is used to collect personal information about one or more attack episodes. The personal information is associated with temporal information for the attack and the personal information and temporal information is stored in at least one storage device associated with the portable electronic device. The stored personal and temporal information may be used to generate one or more reports displaying trends for one or more report metrics. Emergency information related to the disease and stored on the portable electronic device may be output from the portable electronic device in an emergency situation.
Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
Abstract: Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells.
Type:
Grant
Filed:
June 14, 2007
Date of Patent:
May 21, 2013
Assignee:
DYAX Corp.
Inventors:
Henricus Renerus Jacobus Mattheus Hoogenboom, Jurgen Mullberg, Robert C. Ladner